Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesFree Cash FlowNet Cash FlowShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Depreciation & Amortization (CF) (2016 - 2019)

Historic Depreciation & Amortization (CF) for Syndax Pharmaceuticals (SNDX) over the last 5 years, with Q3 2019 value amounting to -$176000.0.

  • Syndax Pharmaceuticals' Depreciation & Amortization (CF) fell 2137.93% to -$176000.0 in Q3 2019 from the same period last year, while for Jun 2020 it was -$176000.0, marking a year-over-year increase of 6794.17%. This contributed to the annual value of $8.0 million for FY2024, which is 3333.33% down from last year.
  • Latest data reveals that Syndax Pharmaceuticals reported Depreciation & Amortization (CF) of -$176000.0 as of Q3 2019, which was down 2137.93% from -$224000.0 recorded in Q2 2019.
  • Syndax Pharmaceuticals' 5-year Depreciation & Amortization (CF) high stood at $190000.0 for Q3 2015, and its period low was -$224000.0 during Q2 2019.
  • Its 5-year average for Depreciation & Amortization (CF) is -$12266.7, with a median of $4000.0 in 2016.
  • Per our database at Business Quant, Syndax Pharmaceuticals' Depreciation & Amortization (CF) soared by 172500.0% in 2017 and then plummeted by 113333.33% in 2018.
  • Syndax Pharmaceuticals' Depreciation & Amortization (CF) (Quarter) stood at $190000.0 in 2015, then tumbled by 136.32% to -$69000.0 in 2016, then soared by 323.19% to $154000.0 in 2017, then plummeted by 194.16% to -$145000.0 in 2018, then fell by 21.38% to -$176000.0 in 2019.
  • Its Depreciation & Amortization (CF) stands at -$176000.0 for Q3 2019, versus -$224000.0 for Q2 2019 and -$180000.0 for Q1 2019.